GNMSF Company Profile and Key Details

Q: Who are the executives of GNMSF?

Mr. Anthony ManciniExecutive Vice President & Chief Operating OfficerMs. Birgitte Stephensen M.Sc.Executive Vice President & Chief Legal OfficerMr. Anthony PaganoExecutive Vice President & Chief Financial OfficerDr. Tahamtan AhmadiExecutive Vice President, Chief Medical Officer & Head of Experimental MedicinesMr. Andrew CarlsenSenior Director, Vice President & Head of Investor RelationsDr. Jan G.J. van de Winkel Ph.D.Co-Founder, Pres & Chief Executive OfficerDr. Judith V. Klimovsky M.D.Executive Vice President & Chief Devel. OfficerDr. Rima Bawarshi Nassar Ph.D.Vice President, Head of Global Regulatory Affairs Oncology & Non-Independent DirectorMr. Martin SchultzSenior Director of Clinical Operations & Non-Independent DirectorMr. Christopher CozicExecutive Vice President & Chief People OfficerDr. Mijke Zachariasse Ph.D.Senior Director, Head of Antibody Research Materials & Non-Independent DirectorMr. Takahiro HamataniSenior Director of Fin. Japan & Non-Independent DirectorMr. Peter RosVice President of Fin.

PNK : GNMSF

Genmab A/S

$268.61

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Genmab A/S (GNMSF) stock remained unchanged at $290.00 a share on OTC. The stock opened at $290.00, fluctuating between $290.00 to $290.00 during the session.

Stock Snapshot

290

Prev. Close

17.87B

Market Cap

290

Day Low

18.87

P/E Ratio

15.37

EPS (TTM)

107.21

Cash Flow per Share

290

Open

61.62M

Number of Shares

290

Day High

98.83%

Free Float in %

483.85

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 24, 2026	290.00	290.00	290.00	290.00	7
Feb 18, 2026	284.40	284.40	284.40	284.40	9
Feb 17, 2026	310.00	310.00	297.25	297.25	25
Feb 11, 2026	300.00	300.00	300.00	300.00	3
Feb 10, 2026	308.00	308.50	308.00	308.00	242
Feb 03, 2026	330.63	330.63	330.63	330.63	70
Jan 27, 2026	340.00	340.00	340.00	340.00	33
Jan 21, 2026	327.25	327.25	327.25	327.25	1
Jan 16, 2026	331.60	331.60	330.37	330.37	37
Jan 15, 2026	336.25	336.25	336.25	336.25	1
Jan 14, 2026	344.00	352.00	344.00	352.00	770
Jan 12, 2026	334.59	334.59	334.59	334.59	7
Jan 09, 2026	340.00	340.00	340.00	340.00	18
Jan 07, 2026	328.00	336.75	328.00	336.75	276
Jan 06, 2026	330.45	330.45	323.68	323.68	8.01K
Dec 31, 2025	314.75	314.75	314.00	314.00	21
Dec 24, 2025	334.00	334.00	333.25	333.25	2.4K
Dec 19, 2025	320.00	325.00	320.00	325.00	89.94K
Dec 15, 2025	319.15	319.15	319.15	319.15	3
Dec 11, 2025	320.00	320.00	320.00	320.00	10.17K

Contact Details

Copenhagen, 1560

Denmark

https://www.genmab.com 457 020 2728

About Company

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 FNCH

-0.05-0.38%

Finch Therapeutics Group, Inc.$13.20 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $170.00 and $352.00. With a market capitalization of about $17.87 billion, Genmab A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.80). Key stats such as the average daily volume over the past year has been around 2.30 thousand shares, volume is running light vs its 52-week average. Headquartered in Copenhagen, None, Genmab A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jan van de Winkel, the company employs approximately 2,638 people and listed since January 05, 2010. Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

Technical Performance

Average 10-day trading volume of 7.00 shares is below the 3-month average of 6.00 thousand, indicating normal recent market interest.

Valuation Metrics

Genmab A/S trades at a P/E ratio of 28.18, slightly below the S&P 500 average, with a price-to-sales ratio of 6.1 and a price-to-book ratio of 3.08 trading at moderately above to book value. The P/FCF stands at 25.65, also below market averages.

Dividend & Fair Value

Genmab A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $945.21. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Genmab A/S earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 32.92%. The prior quarter beat by 35.84%. Over the last six quarters, Apple has recorded several small beats. These include 611.52% in August 08, 2024.

Financial & Profitability Overview

Over the trailing twelve months, Genmab A/S generated $16.47B in revenue, or $249.93 per share. Gross margin was 96.64%, operating margin 32.30%, and net profit margin 26.42%. Returns are healthy, with ROA at 12.33% and ROE at 13.77%.
On valuation metrics, Genmab A/S trades at a P/E of 28.18, P/S of 6.10 and P/B of 3.08. The current ratio is 2.02 and quick ratio is 2.01. Operationally, the company’s inventory turnover is 10.82 and cash conversion cycle is -1827.71 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.95, supported by a cash flow-to-debt ratio of 0.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Genmab A/S posted revenue of $16.47B, down slightly from $14.60B in the prior quarter. Gross profit was $15.92B (margin 96.64%). Operating income was $5.32B (margin 32.3%). Net income was$4.35B (EPS $66.64).
The company ended the quarter with $28.14B in cash and short-term investments, a total debt of $770.00M, and net debt of - $14.10B. Total assets were $35.29B, with equity of $31.61B. Financials further reflected stability, with operating cash flow of $7.38B, free cash flow of $7.00B, and capital expenditures of - $376.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Genmab A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Genmab A/S trading at a premium to the broader market with a P/E of 28.18.

Frequently Asked Questions

What is the current Genmab A/S (GNMSF) stock price?

Genmab A/S (OTC: GNMSF) stock price is $290.00 in the last trading session. During the trading session, GNMSF stock reached the peak price of $290.00 while $290.00 was the lowest point it dropped to. The percentage change in GNMSF stock occurred in the recent session was 0% while the dollar amount for the price change in GNMSF stock was $0.00.

GNMSF's industry and sector of operation?

The OTC listed GNMSF is part of Biotechnology industry that operates in the broader Healthcare sector. Genmab A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GNMSF?

Mr. Anthony Mancini
Executive Vice President & Chief Operating Officer
Ms. Birgitte Stephensen M.Sc.
Executive Vice President & Chief Legal Officer
Mr. Anthony Pagano
Executive Vice President & Chief Financial Officer
Dr. Tahamtan Ahmadi
Executive Vice President, Chief Medical Officer & Head of Experimental Medicines
Mr. Andrew Carlsen
Senior Director, Vice President & Head of Investor Relations
Dr. Jan G.J. van de Winkel Ph.D.
Co-Founder, Pres & Chief Executive Officer
Dr. Judith V. Klimovsky M.D.
Executive Vice President & Chief Devel. Officer
Dr. Rima Bawarshi Nassar Ph.D.
Vice President, Head of Global Regulatory Affairs Oncology & Non-Independent Director
Mr. Martin Schultz
Senior Director of Clinical Operations & Non-Independent Director
Mr. Christopher Cozic
Executive Vice President & Chief People Officer
Dr. Mijke Zachariasse Ph.D.
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Mr. Takahiro Hamatani
Senior Director of Fin. Japan & Non-Independent Director
Mr. Peter Ros
Vice President of Fin.

How GNMSF did perform over past 52-week?

GNMSF's closing price is 2.52% higher than its 52-week low of $170.00 where as its distance from 52-week high of $352.00 is -36.24%.

How many employees does GNMSF have?

Number of GNMSF employees currently stands at 2,638.

Link for GNMSF official website?

Official Website of GNMSF is: https://www.genmab.com

How do I contact GNMSF?

GNMSF could be contacted at phone 457 020 2728 and can also be accessed through its website. GNMSF operates from Kalvebod Brygge 43, Copenhagen, 1560, Denmark.

How many shares of GNMSF are traded daily?

GNMSF stock volume for the day was 7 shares. The average number of GNMSF shares traded daily for last 3 months was 2.3K.

What is the market cap of GNMSF currently?

The market value of GNMSF currently stands at $17.87B with its latest stock price at $290.00 and 61.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2638
Beta	0.8
Sales or Revenue	$16.47B
5Y Sales Change%	4.109%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GNMSF Company Profile and Key Details

Genmab A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways